RESUMEN
Psycho-oncology is a young discipline-in dermatology as well as in the medicine. The topic is heterogeneous and not clearly defined. The proportion of indications for emotional care in oncology is up to 50%, depending on the method of diagnosis. In daily dermatological practice, careful distribution of information and helping with coping are essential in order to not overwhelm the patient. The doctor should ask questions about the patient's expectations, fears, and any unclear items.
Asunto(s)
Trastornos Mentales/diagnóstico , Trastornos Mentales/terapia , Educación del Paciente como Asunto/métodos , Participación del Paciente/métodos , Relaciones Médico-Paciente , Neoplasias Cutáneas/diagnóstico , Neoplasias Cutáneas/terapia , Dermatología/métodos , Alemania , Humanos , Oncología Médica/métodos , Trastornos Mentales/complicaciones , Trastornos Mentales/psicología , Participación del Paciente/psicología , Psicología/métodos , Neoplasias Cutáneas/complicaciones , Neoplasias Cutáneas/psicologíaRESUMEN
The initial steps of any topical therapy are characterized by the degree of liberation of the agent from the ointment base and their penetration into different skin layers. A high percentage of the topically applied prednisolone does not penetrate into the skin and may be removed from the skin surface even after some time. By altering the functional structure of the horny layer and considerably increase of prednisolone liberation from ointment bases urea is a effective penetration promotor also for prednisolone. The increased prednisolone penetration into human skin from urea containing ointment correspond with the degree of blanching results by vasoconstriction test under in vivo conditions. The resulting penetration optimation of prednisolone has two possible applications in topical therapy: an increased therapeutic effect for a given prednisolone concentration and a given therapeutic effect could be obtained with a reduced prednisolone concentration.
Asunto(s)
Prednisolona/administración & dosificación , Administración Tópica , Excipientes , Humanos , Bases Oleosas , Prednisolona/farmacocinética , Absorción Cutánea , UreaRESUMEN
With the liposomal incorporated hydrocortisone a very much improved concentration-time profile was obtained in the different layers of human skin after topical application when compared with conventional hydrocortisone in the ointment. The increased hydrocortisone penetration into human skin correspond with the degree of blanching results by vasoconstriction test. Under in vivo conditions the influence of liposomal hydrocortisone on percutaneous resorption was investigated. In guinea pigs a decreased serum concentration and urinary excretion of hydrocortisone could be demonstrated. Thus, hydrocortisone-loaded liposomes, when applied topically, act as a selective drug delivery system, it can be provide increased therapeutic efficacy and, simultaneously, decreased unwanted systemic effects. The significance of liposomal incorporated attenuative and higher potent glucocorticoids in external therapy is discussed.
Asunto(s)
Hidrocortisona/farmacocinética , Absorción Cutánea , Animales , Cobayas , Hidrocortisona/administración & dosificación , Hidrocortisona/sangre , Técnicas In Vitro , Liposomas , Masculino , EspectrofotometríaRESUMEN
HISTORY: A 57-year-old man was admitted with hemorrhagic papules and necrotising nodules on both elbows and upper legs. Recurrent arthralgia occurred. INVESTIGATIONS: The skin biopsy showed a cutaneous necrotising vasculitis. Positive test results for c-ANCA and proteinase 3 antibodies and a slightly increased WBC and a mild proteinuria were noticeable. DIAGNOSIS, TREATMENT AND COURSE: The diagnosis of an early systemic Wegener's granulomatosis was based on elevated proteinase 3-titres and cutaneous histologic findings as necrotising vasculitis and granulomatous inflammation. Treatment with prednisolone followed by methotrexate resolved the cutaneous symptoms and the arthralgia completely. Three months later the patient developed a progredient methotrexate toxicity caused by a glomerulonephritis. CONCLUSION: Wegener's granulomatosis should be considered if a cutaneous necrotising vasculitis is diagnosed. A cutaneous manifestation could be an early symptom. Methotrexate could be used for treatment of mild courses of Wegener's disease without renal involvement.
Asunto(s)
Granulomatosis con Poliangitis/diagnóstico , Dermatosis de la Pierna/diagnóstico , Enfermedades Cutáneas Vasculares/diagnóstico , Anticuerpos Anticitoplasma de Neutrófilos/sangre , Biopsia , Quimioterapia Combinada , Glomerulonefritis/inducido químicamente , Granulomatosis con Poliangitis/inmunología , Humanos , Inmunosupresores/uso terapéutico , Inmunosupresores/toxicidad , Dermatosis de la Pierna/inmunología , Recuento de Leucocitos , Masculino , Metotrexato/uso terapéutico , Metotrexato/toxicidad , Persona de Mediana Edad , Mieloblastina/inmunología , Necrosis , Prednisolona/uso terapéutico , Prednisolona/toxicidad , Piel/patología , Enfermedades Cutáneas Vasculares/inmunologíaRESUMEN
Urea ointments and emulsions are excellently suited for the care and supportive therapy of neurodermatitis patients. In treating children and in the case of acutely irritated skin conditions, we have arrived at a concentration of 5% urea. All other dermatological conditions can be easily and effectively treated with a 10% urea preparation. It goes without saying that galenics also play an important role. An unbalanced composition can lead to poor results. In a short-term test (180 minutes) and in a long-term test (7 days), we tested the moisture level of the corneal layer with the corneometer in a climate-controlled room. We were able to show that urea in hydrous topical agents ensures acceleration of corneal hydration and helps retain water in the corneal layer. Thus, urea preparations can also be especially recommended for use in patients with neurodermatitis.
Asunto(s)
Dermatitis Atópica/metabolismo , Sudoración/efectos de los fármacos , Urea/farmacología , Pérdida Insensible de Agua/efectos de los fármacos , Dermatitis Atópica/tratamiento farmacológico , Humanos , Pomadas , Urea/administración & dosificación , Urea/uso terapéuticoRESUMEN
Vulvodynia is a complex syndrome of chronic vulvar pain. It is divided into several subtypes: 1. cyclic vulvovaginitis (pain occurs after coitus), 2. vulvar vestibulitis syndrome (pain mainly with intercourse), 3. dysaesthetic vulvodynia (psychosomatic; diagnosis of exclusion), 4. vulvar dermatoses (e.g. pemphigus vulgaris, contact dermatitis). Additional causes have been described in single cases. Though vulvodynia is often accompanied by psychological distress, somatic causes have to be considered in each case.
Asunto(s)
Dolor , Enfermedades de la Piel/diagnóstico , Enfermedades de la Vulva , Adolescente , Adulto , Coito , Dermatitis por Contacto/diagnóstico , Diagnóstico Diferencial , Femenino , Humanos , Ciclo Menstrual , Persona de Mediana Edad , Dolor/diagnóstico , Dolor/etiología , Pénfigo/diagnóstico , Trastornos Psicofisiológicos/diagnóstico , Enfermedades de la Vulva/clasificación , Enfermedades de la Vulva/diagnóstico , Enfermedades de la Vulva/etiología , Vulvovaginitis/diagnósticoRESUMEN
21 patients suffering from chronic urticaria were treated with Ketotifen (2 X 1 mg/d) for 4 weeks. The suppression of weals and pruritus, the side effects in comparison with antihistamines, as well as the effect after finishing therapy have been studied. Ketotifen has a good suppressing effect on weals and pruritus. The general tolerance of the preparation is good, as well. Thus Ketotifen may be regarded as an additional possibility concerning treatment of chronic urticaria.
Asunto(s)
Cetotifen/uso terapéutico , Urticaria/tratamiento farmacológico , Adolescente , Adulto , Niño , Enfermedad Crónica , Femenino , Humanos , Cetotifen/efectos adversos , Masculino , Persona de Mediana EdadRESUMEN
73 patients with fungal infections due to dermatophytes (49), yeasts (16) and Malassezia furfur (8) could be cured clinically in 71% and mycologically in 88% of cases by the application of Mycontral-Lotion or -cream twice daily for 33 days on average. In 28% improvement could be reached, in one patient the therapy failed. Treatment is simple, clean and well acceptable. Side-effects occurred as slight redness, transient burning and pruritus on the eroded skin in the initial phase in 8 patients (11%). Mykontral contains 1% tioconazole as a modern imidazol compound. It has been characterized as an effective topical broad spectrum antimycotic agent. Its introduction and application in the GDR is to be recommended.
Asunto(s)
Antifúngicos/administración & dosificación , Dermatomicosis/tratamiento farmacológico , Imidazoles/administración & dosificación , Administración Tópica , Adolescente , Adulto , Anciano , Candidiasis Cutánea/tratamiento farmacológico , Niño , Ensayos Clínicos como Asunto , Femenino , Humanos , Masculino , Persona de Mediana Edad , Tiña/tratamiento farmacológicoRESUMEN
Several attempts have been made to optimize the efficiency of topical glucocorticoids (GC) and, at the same time, to minimize their side effects. In this respect, we should first consider attenuated GC. Dependent on the urea concentration, hydrocortisone (HC) in combination with urea results in both a considerable increase of the HC liberation from the ointment base, as well as an increased penetration rate of HC into the individual skin layers. If we apply these mechanisms to a preparation containing low HC concentrations, a given therapeutic effect can be obtained with definitely reduced HC concentrations. On the other hand, the therapeutic efficiency or the penetration rate of GC can not be deduced from the galenic formulation, the drug concentration, or the amount of urea.
Asunto(s)
Antiinflamatorios/farmacocinética , Absorción Cutánea/efectos de los fármacos , Administración Tópica , Antiinflamatorios/administración & dosificación , Técnicas de Cultivo , Relación Dosis-Respuesta a Droga , Femenino , Humanos , Hidrocortisona , Vehículos FarmacéuticosRESUMEN
A polychemotherapy (DTIC, vincristine, ftorafur, hydroxycarbamide) devised with reference to the results of short-term sensitivity tests in cell culture is compared with single-agent chemotherapy with DTIC in malignant melanoma. Effectiveness was investigated in a randomized prospective study in cases of high-risk melanoma in clinical stage I, in clinical stage II after lymphadenectomy and in clinical stage III after tumour debulking. The results recorded allow no positive effects of either form of chemotherapy in stage I disease compared with surgical treatment only in a control group. In contrast, a statistically significant advantage of the polychemotherapy was noted in stage II compared with a control group. There was no significant difference in the results of treatment between the two forms of chemotherapy in stage III. No complete remissions of long duration have been achieved.
Asunto(s)
Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Melanoma/tratamiento farmacológico , Neoplasias Cutáneas/tratamiento farmacológico , Adolescente , Adulto , Anciano , Bleomicina/administración & dosificación , Terapia Combinada , Dacarbazina/administración & dosificación , Estudios de Seguimiento , Humanos , Lomustina/administración & dosificación , Metástasis Linfática , Melanoma/patología , Melanoma/cirugía , Persona de Mediana Edad , Estadificación de Neoplasias , Estudios Prospectivos , Ensayos Clínicos Controlados Aleatorios como Asunto , Neoplasias Cutáneas/patología , Neoplasias Cutáneas/cirugía , Vincristina/administración & dosificaciónRESUMEN
Using a multilayer membrane system and human horny layer the difference in the penetration of salicylic acid (SA) and its sodium (Na-S) and choline (Ch-S) salts from topical formulations was studied. It was found Na-S and Ch-S were markedly accumulated in the first membrane of the three layer membrane system used. In contrast, a rapid penetration into all three membranes was observed when SA was used. Similar penetration profiles were obtained in human horny layer. Hence, the use of the salts of SA appears to be more suitable for the application as keratolytic.
Asunto(s)
Epidermis/metabolismo , Salicilatos/farmacocinética , Absorción Cutánea/fisiología , Humanos , Ácido SalicílicoRESUMEN
Malignant atrophic papulosis (Degos'disease) is very rare and shows characteristic clinical symptoms. We report on a patient with Degos'disease who died as a result of intestinal involvement. The clinical and histological changes are indicative of a systemic disease.
Asunto(s)
Granuloma/patología , Infarto/patología , Perforación Intestinal/patología , Intestinos/irrigación sanguínea , Enfermedades del Yeyuno/patología , Enfermedades de la Piel/patología , Piel/irrigación sanguínea , Atrofia , Diagnóstico Diferencial , Humanos , Intestinos/patología , Masculino , Persona de Mediana Edad , Necrosis , Piel/patología , Tromboangitis Obliterante/patologíaRESUMEN
Collective investigations of fertility in childless married couples were carried out in 9 andrological health centres of the GDR. Analysis of 1937 spermatograms in comparison to fertility after 1 to 2 years shows: (1) Fertility decreases significantly at sperm density nearly 10 million per ml. (2) Motility below 60 per cent caused reduced fertility. Normal motility is more important than normal density of spermatozoa. (3) Fructose level doesn't correlate to motility or fertility of man.
Asunto(s)
Infertilidad Masculina/diagnóstico , Recuento de Células , Fructosa/análisis , Humanos , Masculino , Anamnesis , Semen/análisis , Motilidad Espermática , EspermatozoidesRESUMEN
OBJECTIVE: To assess the safety, tolerability and efficacy of a new cyclosporin A (CyA) microemulsion formulation, Sandimmun Neoral (Neoral), in patients with severe psoriasis that was stable on CyA administered as Sandimmun (SIM). METHODS: In this 24-week, open, randomized, prospective, multicentre trial, 28 patients continued on the same dosage of SIM, while 30 converted to Neoral at 2.5 mg/kg/day or a dosage equivalent to their pre-conversion SIM dosage. During the study, dosages could be adjusted to maintain efficacy, because of adverse events or after disease stabilization. The maximum permitted dosage for either formulation was 5.0 mg/kg/day. Primary efficacy criteria were change in Psoriasis Area and Severity Index (PASI) from baseline and time to relapse. RESULTS: The dosage was increased to maintain efficacy in 22 patients (Neoral 13; SIM 9) and 20 dose reductions for safety were required (Neoral 14, SIM 6). In both groups, PASI scores remained stable throughout and relapses were primarily a result of dosage reduction after disease stabilization. No significant difference was found between groups in the proportion of patients remaining relapse-free. Adverse events were recorded in 20 patients receiving Neoral and 14 receiving SIM. Most drug-related events were of mild or moderate severity and reflected the known CyA side-effect profile. Dose titration guidelines ensured that mean blood pressure and serum creatinine concentrations remained stable in both groups. CONCLUSIONS: If the guidelines for CyA use are followed and the Neoral dosage does not exceed 5 mg/kg/day, conversion of stable patients with severe psoriasis from SIM to Neoral should present no clinically relevant safety or tolerability problems and efficacy of treatment is maintained.